Latest Breaking News On - சிகிச்சை ஆஃப் புற்றுநோய் - Page 2 : comparemela.com

Oslo, Norway, 18 February 2021 - PCI Biotech’s (OSE: PCIB) fourth quarter and preliminary full year 2020 interim report will be released on 24 February 2021 at 07.00 CET. The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com. A results presentation (in English) will be held through a live webcast at 08.30 CET the same day. The webcast can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation. It will be possible to post written questions through the webcast console or through a teleconference facilitated for investors intending to ask questions verbally during the Q&A session. For further information, please contact:Ronny Skuggedal, CFOEmail: rs@pcibiotech.noMobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatm

Interim reportTreatment of cancerஇடைக்கால அறிக்கைசிகிச்சை ஆஃப் புற்றுநோய்